Guelph facility manufactures
more than 100 different medications including Tylenol®, Motrin®,
Benylin® and Sudafed®
GUELPH,
ON, Nov. 4, 2024 /CNW/ - Kenvue Canada Inc., a
division of Kenvue Inc. (NYSE: KVUE) ("Kenvue"), the world's
largest pure-play consumer health company by revenue and maker of
iconic brands such as Tylenol®, Aveeno, Listerine® and Neutrogena®,
announced the completion of its newly expanded manufacturing
facility in Guelph. This expansion
marks a significant milestone in Kenvue's more than 50-year
commitment to the region and strengthening supply resilience
globally.
"The Kenvue Guelph site expansion enables us to significantly
increase our production capacity to respond to demand, helping
ensure essential medicines are readily available to consumers when
needed most," said Katie Decker,
Managing Director, Kenvue Canada. "This further supports government
and healthcare leaders to respond swiftly to public health
emergencies, and underscores Kenvue's commitment to the well-being
of Canadians and the approximately 1.2 billion consumers whose
lives we touch around the world."
The expansion was generously supported by funding from the
Ontario government's Ontario
Together Fund. This fund helps businesses improve healthcare,
strengthen local manufacturing, and support innovative technologies
in Ontario.
"Our newly expanded facility, which increases our manufacturing
footprint by 7.5 per cent, is a major step forward in growing to
meet the evolving healthcare needs of Canadians," said Michael
Syntax, Guelph Plant Leader, Kenvue Canada. "We are grateful for
the support from the Government of Ontario, which has been instrumental in making
this project a reality."
"On behalf of the Government of Ontario, we congratulate Kenvue on their newly
expanded manufacturing facility in Guelph, which we were proud to support through
the Ontario Together Fund," said Vic
Fedeli, Ontario Minister of
Economic Development, Job Creation and Trade. "By building up our
domestic pharmaceutical manufacturing capabilities, we will
position Ontario as a leader in
drug development and life sciences innovation while ensuring we are
well-prepared to face any future supply chain challenges."
"The Kenvue manufacturing site in Guelph has been an important part of the
community for decades, both for providing good jobs and supporting
the local economy," said Cam
Guthrie, Mayor of Guelph.
"We are delighted to see the completion of this expansion."
Kenvue is committed to delivering science-backed, care-forward
solutions that are endorsed by healthcare professionals to support
everyday care. The company's Guelph facility has been the home to the
Canadian arm of the company's manufacturing footprint since 1978.
Today, the facility manufactures the majority of the Tylenol®
available in Canada. It is also
home to 50 acres of green space and is certified through the
Wildlife Habitat Council.
About Kenvue
Kenvue is the world's largest pure-play consumer health company
by revenue. Built on more than a century of heritage, our iconic
brands, including Aveeno®,
BAND-AID® Brand, Johnson's®,
Listerine®, Neutrogena® and
Tylenol®, are science-backed and recommended by
healthcare professionals around the world. At Kenvue, we believe in
the extraordinary power of everyday care and our teams work every
day to put that power in consumers' hands and earn a place in their
hearts and homes. Learn more at www.kenvue.com.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding the expansion of Kenvue Canada Inc.'s manufacturing
facility in Guelph.
Forward-looking statements may be identified by the use of words
such as "plans," "expects," "will," "anticipates," "estimates" and
other words of similar meaning. The reader is cautioned not to rely
on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions
prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the
expectations and projections of Kenvue and its affiliates.
A list and descriptions of risks, uncertainties and other
factors can be found in Kenvue's filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the fiscal year ended December 31,
2023 and subsequent Quarterly Reports on Form 10-Q and other
filings, available at www.kenvue.com or on request from Kenvue.
Kenvue and its affiliates undertake no obligation to update any
forward-looking statements, whether as a result of new information,
future events or developments or otherwise.
*Tylenol®, Aveeno®, Listerine® and Neutrogena® are brands of
Kenvue Canada Inc., a subsidiary of Kenvue Inc.
SOURCE Kenvue
